thalidomide has been researched along with Mesothelioma in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment." | 9.17 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013) |
| "The purpose of this study was to describe the experience with the anti-angiogenic agent thalidomide in the treatment of patients with a malignant pleural mesothelioma (MPM)." | 9.11 | Thalidomide in patients with malignant pleural mesothelioma. ( Baas, P; Boogerd, W; Custers, F; Dalesio, O; Haringhuizen, A; van Zandwijk, N, 2005) |
| " In conclusion, thalidomide alone, or in combination with cisplatin/gemcitabine, controlled disease for >6 months in ∼30% of patients." | 5.38 | The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. ( Abraham, R; Clarke, S; Cullen, M; Davey, R; Harvie, R; Kao, SC; Kerestes, Z; Marx, G; Paturi, F; Pavlakis, N; Taylor, R, 2012) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 5.32 | [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. ( Hada, M; Kazuhiro, M, 2004) |
| "In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment." | 5.17 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013) |
| "The purpose of this study was to describe the experience with the anti-angiogenic agent thalidomide in the treatment of patients with a malignant pleural mesothelioma (MPM)." | 5.11 | Thalidomide in patients with malignant pleural mesothelioma. ( Baas, P; Boogerd, W; Custers, F; Dalesio, O; Haringhuizen, A; van Zandwijk, N, 2005) |
| " In conclusion, thalidomide alone, or in combination with cisplatin/gemcitabine, controlled disease for >6 months in ∼30% of patients." | 1.38 | The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. ( Abraham, R; Clarke, S; Cullen, M; Davey, R; Harvie, R; Kao, SC; Kerestes, Z; Marx, G; Paturi, F; Pavlakis, N; Taylor, R, 2012) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 1.32 | [A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. ( Hada, M; Kazuhiro, M, 2004) |
| "Fumagillin can also inhibit cancer cell proliferation, implying that MetAP2 may play a quite complex role in tumor progression." | 1.31 | Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. ( Catalano, A; Procopio, A; Robuffo, I; Romano, M; Strizzi, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buikhuisen, WA | 1 |
| Burgers, JA | 1 |
| Vincent, AD | 1 |
| Korse, CM | 1 |
| van Klaveren, RJ | 1 |
| Schramel, FM | 1 |
| Pavlakis, N | 3 |
| Nowak, AK | 1 |
| Custers, FL | 1 |
| Schouwink, JH | 1 |
| Gans, SJ | 1 |
| Groen, HJ | 1 |
| Strankinga, WF | 1 |
| Baas, P | 2 |
| Pass, HI | 1 |
| Dhalluin, X | 1 |
| Scherpereel, A | 1 |
| Kao, SC | 2 |
| Harvie, R | 2 |
| Paturi, F | 1 |
| Taylor, R | 1 |
| Davey, R | 1 |
| Abraham, R | 1 |
| Clarke, S | 2 |
| Marx, G | 1 |
| Cullen, M | 1 |
| Kerestes, Z | 1 |
| Vardy, J | 1 |
| Chatfield, M | 1 |
| van Zandwijk, N | 2 |
| Hada, M | 1 |
| Kazuhiro, M | 1 |
| Boogerd, W | 1 |
| Dalesio, O | 1 |
| Haringhuizen, A | 1 |
| Custers, F | 1 |
| Biswas, G | 1 |
| Narayanan, P | 1 |
| Bhagwat, R | 1 |
| Khadwal, A | 1 |
| Bakshi, AV | 1 |
| Parikh, PM | 1 |
| Deaner, P | 1 |
| Catalano, A | 1 |
| Romano, M | 1 |
| Robuffo, I | 1 |
| Strizzi, L | 1 |
| Procopio, A | 1 |
1 review available for thalidomide and Mesothelioma
| Article | Year |
|---|---|
Chemotherapy and radiotherapy for mesothelioma.
Topics: Antineoplastic Agents; Asbestos; Combined Modality Therapy; Gefitinib; Genetic Therapy; Histone Deac | 2011 |
3 trials available for thalidomide and Mesothelioma
| Article | Year |
|---|---|
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Ca | 2013 |
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; C-Reactive Protein; Female; | 2013 |
Thalidomide in patients with malignant pleural mesothelioma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female | 2005 |
6 other studies available for thalidomide and Mesothelioma
| Article | Year |
|---|---|
Mesothelioma: closer to the target?
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neopla | 2013 |
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cisplatin; Clinical | 2012 |
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Combined Modality Therapy; Dru | 2004 |
Thalidomide in primary peritoneal mesothelioma.
Topics: Angiogenesis Inhibitors; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Thalidomide | 2006 |
Thalidomide for distressing night sweats in advanced malignant disease.
Topics: Fever; Humans; Hyperhidrosis; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Thalidomide | 1998 |
Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity.
Topics: Amino Acid Chloromethyl Ketones; Aminopeptidases; Angiogenesis Inhibitors; Apoptosis; Caspase 3; Cas | 2001 |